Iskra Reic - AstraZeneca PLC Executive Therapies
| 0A4J Stock | 63.80 1.80 2.74% |
Executive
Iskra Reic is Executive Therapies of AstraZeneca PLC ADR
| Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.085 % which means that it generated a profit of $0.085 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1666 %, meaning that it generated $0.1666 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. Total Assets is likely to drop to about 69.2 B in 2024. Other Assets is likely to drop to about 3.9 B in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Oliver Bruzek | CompuGroup Medical AG | N/A | |
| Bernadette UdeWetherell | Science in Sport | N/A | |
| Muna Khan | Science in Sport | N/A | |
| Jatin CFA | Cognizant Technology Solutions | 49 | |
| Thea Hayden | Cognizant Technology Solutions | N/A | |
| Balu Ayyar | Cognizant Technology Solutions | 62 | |
| Helge Wei | CompuGroup Medical AG | N/A | |
| Alex Spokoiny | Check Point Software | N/A | |
| Srinivasan Veeraraghavachary | Cognizant Technology Solutions | 64 | |
| Sharon Schusheim | Check Point Software | N/A | |
| Shira Yashar | Check Point Software | N/A | |
| Stefanie Peters | CompuGroup Medical AG | 55 | |
| Megan Blaylock | Science in Sport | N/A | |
| Claudia Thom | CompuGroup Medical AG | 53 | |
| Itai Greenberg | Check Point Software | N/A | |
| Michael Franz | CompuGroup Medical AG | N/A | |
| Alexander Weimer | CompuGroup Medical AG | N/A | |
| Surya Gummadi | Cognizant Technology Solutions | 47 | |
| Gaurav Chand | Cognizant Technology Solutions | N/A | |
| Michael Lindsell | Allianz Technology Trust | 63 | |
| Guojun Lou | Sunny Optical Technology | 59 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 |
AstraZeneca PLC ADR Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CEO Officer | ||
| Pam Cheng, EVP Board | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Katarina Ageborg, Chief Sustainability | ||
| Jeffrey Pott, Chief CHRO | ||
| Ruud Dobber, Executive Unit | ||
| Chris Sheldon, Head Relations | ||
| David Fredrickson, Executive Unit | ||
| Jeffrey JD, Chief CHRO | ||
| Gonzalo Vina, Head Relations | ||
| Andrew Barnett, Head Relations | ||
| Menelas Pangalos, Executive VicePresident | ||
| Leon Wang, Executive President | ||
| Susan MD, Executive Development | ||
| Iskra Reic, Executive Therapies |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 128.51 B | ||||
| Shares Owned By Institutions | 16.75 % | ||||
| Revenue | 51.21 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 18.39 B | ||||
| Net Income | 5.96 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.